Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 12:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Schizophrenia
Interventions
Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Conditions
Bipolar I Disorder
Interventions
olanzapine, placebo, divalproex
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Hialeah, Florida
Conditions
Schizophrenia
Interventions
CX516 (Ampakine)
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pathological Gambling
Interventions
olanzapine, sugar pill
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
Interventions
Olanzapine, Placebo Oral Tablet
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
30 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
San Francisco, California • Kansas City, Missouri • Chapel Hill, North Carolina + 2 more
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Withdrawn Phase 1Phase 2 Interventional

Nicotinic Receptors and Schizophrenia

NCT02538081
Conditions
Schizophrenia
Interventions
Risperidone plus Placebo, Risperidone plus DMXB-A
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Obesity
Interventions
IHBG-10, Placebo
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Completed Not applicable Interventional Results available

Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

NCT01170117
Conditions
Anorexia Nervosa
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • White Plains, New York + 1 more
Completed Phase 4 Interventional Results available

Short Term Rescue Study of Olanzapine

NCT00186017
Conditions
Bipolar Disorder
Interventions
Olanzapine/Zyprexa
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Adults With Schizophrenia

NCT01903837
Conditions
Schizophrenia
Interventions
Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 43 more
Conditions
Weight Gain
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Autistic Disorder
Interventions
olanzapine (Zyprexa), Placebo
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
3 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Green Tea, Placebo
Dietary Supplement · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Schizophrenia
Interventions
Ondansetron followed by placebo, Placebo followed by Ondansetron
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Borderline Personality Disorder
Interventions
Olanzapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
National City, California • New Haven, Connecticut • Indianapolis, Indiana + 4 more
Conditions
Schizophrenia, Psychotic Disorders
Interventions
naltrexone, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Olanzapine 5 MG, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Agitation in Adolescents and Young Adults With ASD
Interventions
INP105, Placebo
Combination Product
Lead sponsor
Impel Pharmaceuticals
Industry
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Portland, Maine • Cincinnati, Ohio
Conditions
Schizophrenia
Interventions
LY2140023, Placebo, Standard of Care
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Conditions
Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions
Olanzapine, Amantadine, Olanzapine and placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Schizophrenia, Alcohol Use Disorder
Interventions
Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
58
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 50 more